Headquartered in Cambridge, Mersana is working on an antibody-drug conjugate platform that is designed for the delivery of drugs; these conjugates can be loaded with a drug payload that is released once inside a targeted cancer cell.
By Chris Reidy| Globe Staff June 24, 2014
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢